that patients can become sensitised to food allergens through an impaired skin barrier. We describe 5 patients with inflammatory skin conditions who have developed clinically significant mammalian milk allergy in the context of using goat's milk skin products.
Results: Five patients were found to have positive goat's milk and/or sheep's milk sIgE. Two out of the 5 patients had evidence of crosssensitisation to cow's milk and were cautioned to avoid all dairy products. All 5 sIgE+ patients had a history of severe anaphylaxis to either goat's cheese, sheep's cheese or feta with at least 1 life threatening feature (hypotension, tongue or throat angioedema, difficulty breathing). All patients identified had inflammatory skin conditions (either Eczema or Psoriasis) and had been using goat's milk soap and/or moisturiser as a topical treatment. Three out of 5 patients had evidence of atopy with comorbid allergic rhinitis, asthma or both. Most patients had a significantly elevated total serum IgE, with an average level of 365 kUA/L.
Conclusion:
Use of goat's milk soap for the management of inflammatory skin conditions appears to be associated with clinically significant sensitisation and new-onset allergy to goat's milk based foods. Some patients also develop cross-sensitisation to other mammalian milk proteins, mandating a diet devoid of all dairy products. Patients with inflammatory skin conditions should be cautioned to avoid using food-based soaps and moisturisers. Background: Peanut allergy, a potentially life-threatening condition, has emerged as a major public health concern in developed countries. There are currently no approved treatment options, with dietary avoidance being the only recommended strategy for prevention of fatal anaphylactic reactions. We propose the use of a novel, proprietary Sementis Copenhagen Vector (SCV)-based peanut hypoallergenic vaccine (SCV-PHAV) to induce sustained unresponsiveness and immune tolerance to peanuts, an objective that eludes current immunotherapy modalities in allergy.
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Methods:
We established an ex vivo human dendritic cells (DCs): CD4 + T cell culture system to investigate the capacity of SCV-PHAV instructed dendritic cells (DCs) to facilitate the production of a tolerant Th1-biased peanut-specific CD4 + T cell response. Briefly, monocyte-derived DCs and CD4 + T cells were isolated from the blood of peanut allergic patients. Peanut-pulsed and SCV-PHAV vaccinated DCs were incubated with CD4 + T cells for 2 weeks. At the end of the incubation period, cultures were labelled with a proliferation dye, re-stimulated with peanut extract and the cytokine profiles of proliferating antigen-specific T cells was examined by flow cytometry.
Results: A significantly higher Th1/Th2 ratio was detected in SCV-PHAV vaccinated cultures compared to peanut-pulsed cultures (n = 5). A consistent increase was observed in separate ex vivo DC:CD4 T cultures set up 6-months apart from the same patient, confirming both assay reproducibility and vaccine efficacy. In addition, we were able to demonstrate an antigen-specific Th1 bias following long-term cultures (5-6 weeks) in the presence of peanut antigens.
Conclusion:
The SCV-PHAV vaccine can modulate the cytokine signatures of peanut-reactive CD4 + T cells from an allergic, Th2-biased to a tolerant, Th1-biased profile. Background: Nut banning in schools is thought to be common despite Victorian Government guidelines recommending against this policy. This study sought to evaluate the Anaphylaxis Risk Minimisation Strategies, including nut banning, that are used by schools in Melbourne.
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Methods:
In 2015-2016, we administered an 8-item phone questionnaire to a staff member at each randomly-selected school in metropolitan Melbourne that participated in the SchoolNuts study. Questionnaire items assessed schools' use of different Anaphylaxis Risk Minimisation Strategies that the government guidelines recommend, recommend against or do not specifically refer to. We described the use of each strategy and its association with the following school factors: type (government, non-government), level (primary/P-12, secondary), size and Index of Community Socio-Educational Advantage.
Results: Of 229 schools approached, 221 (97%) completed the questionnaire. The strategies recommended for use by the guidelines were each implemented by over half of schools: 'No food sharing' policy, 68%; 'Wash hands before/after eating' policy, 56%; Ban on foods (e.g. nuts) used in cooking class, 54%. Strategies that the guidelines recommend against were in place at less than one third of schools: Ban nuts from the whole school, 20%; Ban nuts from classes with nut-allergic student, 30%. Strategies not specifically referred to by the guidelines were utilised by a minority of schools: Special tables for allergic students to eat at, 13%; Allergic students excluded from camps/excursions, 2%; Allergic students excluded from cooking class, 1%. Overall, being a school with primary level students was the factor most strongly associated with implementation of strategies recommended for use, against use and not referred to by the guidelines.
Conclusions:
The majority of schools in Melbourne followed the government guidelines for implementation of Anaphylaxis Risk Minimisation Strategies, however, there was significant variation by school level. Despite guideline recommendations against this policy, up to 30% of schools banned nuts. 
